Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Children's Hospital of Chongqing Medical University | OTHER |
Not provided
Not provided
Not provided
In preterm infants with neonatal respiratory distress syndrome (NRDS), exogenous pulmonary surfactant(PS) replacement therapy is one of the most important therapeutic breakthrough to reduce neonatal mortality. Nowadays, PS is commonly used in newborn infants with respiratory distress, but the incidences of bronchopulmonary dysplasia(BPD) and/or death are inconsistent. The result indicates that not all preterm infants with respiratory distress can be beneficial from PS.
In 2017, the international neonatal ARDS (NARDS) collaborative group provides the first consensus definition for NARDS. And whether or not PS being beneficial for preterm infants with NARDS remains unknown.
To date, PS is not recommended to adult and pediatric ARDS. Meantime, systematic review indicates that PS does not demonstrate statistically significant beneficial effects on reducing the mortality and the rate of BPD in term and late preterm infants with meconium aspiration syndrome(MAS). Therefore, a reasonable speculation is that preterm infants with NARDS do not benefit from one dose of PS. And the speculation can explain why not all preterm infants with respiratory distress can be beneficial from PS. In the era of pre-NARDS, the preterm infants fulfilling the definition of NARDS may have been considered as NRDS in the first three days after birth.
According to the diagnostic criteria of NARDS, a key procedure for diagnosis of NARDS is to exclude the newborn infants with NRDS. But no detailed procedures are available to differentiate NRDS from NARDS.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| one dose of surfactant | the preterm infants diagnosed with NRDS and/or NARDS will be administrated with only one dose of surfactant |
| |
| two and more doses of surfactant | the preterm infants diagnosed with NRDS and/or NARDS will be administrated with two and more doses of surfactant |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| one dose of surfactant replacement | Drug | the preterm infants diagnosed with NRDS and/or NARDS will be administrated with only one dose of surfactant |
|
| Measure | Description | Time Frame |
|---|---|---|
| bronchopulmonary dysplasia(BPD) | the preterm infants will be diagnosed with BPD | at 36 weeks' gestational age or before discharge from hospital |
| death | the preterm infants die | at 36 weeks' gestational age or before discharge from hospital |
| BPD and/or death | the preterm infants will be diagnosed with BPD and/or death | at 36 weeks' gestational age or before discharge from hospital |
| the predictive powers of one dose of surfactant to diagnose NRDS | the sensitivity and accuracy of one dose of surfactant to diagnose NRDS | seven days after birth |
| the predictive powers of two and more doses of surfactant to diagnose NARDS | the sensitivity and accuracy of two and more doses of surfactant to diagnose NARDS | seven days after birth |
| Measure | Description | Time Frame |
|---|---|---|
| intraventricular hemorrhage(IVH) | the preterm infants will be diagnosed with IVH | before discharge or 36 weeks' gestational age |
| air leak | the preterm infants will be diagnosed with air leak |
Not provided
Inclusion Criteria:
Eligibility requirements for neonates were as follows:
Exclusion Criteria:
one of the following criteria will be needed
Not provided
Not provided
Not provided
Preterm infants diagnosed with NRDS or NARDS were eligible. The diagnosis of NARDS was according to the criteria established by Montreux conference in 2017.The diagnosis of NRDS was according to the criteria established by European Consensus Guideline for the management of NRDS in 2019
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Chen Long, MD, PhD | Contact | +8613883559467 | neuroclong@126.com |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Chen | Recruiting | Chongqing | Chongqing Municipality | 400042 | China |
the data will be accessed after two years of study accomplishment
preliminary estimate in 2025
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| two and more doses of surfactant replacement | Drug | the preterm infants diagnosed with NRDS and/or NARDS will be administrated with two and more doses of surfactant |
|
| at 36 weeks' gestational age or before discharge from hospital |
| periventricular leukomalacia(PVL) | the preterm infants will be diagnosed with PVL | at 36 weeks' gestational age or before discharge from hospital |
| necrotizing enterocolitis(NEC) | the preterm infants will be diagnosed with NEC | at 36 weeks' gestational age or before discharge from hospital |
| patent ductus arteriosis(PDA) | the preterm infants will be diagnosed with PDA | at 36 weeks' gestational age or before discharge from hospital |
| late-onset sepsis(LOS) | the preterm infants will be diagnosed with LOS | at 36 weeks' gestational age or before discharge from hospital |
| ID | Term |
|---|---|
| D012128 | Respiratory Distress Syndrome |
| D047928 | Premature Birth |
| C580477 | Surfactant Dysfunction |
| ID | Term |
|---|---|
| D008171 | Lung Diseases |
| D012140 | Respiratory Tract Diseases |
| D012120 | Respiration Disorders |
| D007752 | Obstetric Labor, Premature |
| D007744 | Obstetric Labor Complications |
| D011248 | Pregnancy Complications |
| D005261 | Female Urogenital Diseases and Pregnancy Complications |
| D000091642 | Urogenital Diseases |
Not provided
Not provided